Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery

Cell Chemical Biology

Volumn 23, Issue 7, 2016, Pages 862-874

  Wang, Yuan ^a   Cornett, Allen ^a   King, Fred J ^c   Mao, Yi ^b   Nigsch, Florian ^d   Paris, C Gregory ^a   McAllister, Gregory ^a   Jenkins, Jeremy L ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; CHEMBL 2419697; DINACICLIB; FORMOTEROL; HMS 1899N 20; REFAMETINIB; RUBOXISTAURIN; RUXOLITINIB; SALMETEROL; SCHEMBL 346145; SCHEMBL 3798498; SCHEMBL 3799018; SCHEMBL 8108556; SOTRASTAURIN; STAUROSPORINE; UNCLASSIFIED DRUG; VORINOSTAT; MOLECULAR PROBE;

ARTICLE; COMPARATIVE STUDY; DRUG SCREENING; EVIDENCE BASED PRACTICE; HUMAN; IC50; IN VITRO STUDY; META ANALYSIS (TOPIC); QUALITATIVE ANALYSIS; SUPERVISED MACHINE LEARNING; WNT SIGNALING PATHWAY; AUTOMATION; CELL LINE; CHEMICAL DATABASE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; META ANALYSIS; MOLECULAR PROBE; PHENOTYPE;

AUTOMATION; CELL LINE; DATABASES, CHEMICAL; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR PROBES; MOLECULAR STRUCTURE; PHENOTYPE;

EID: 84978768131     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2016.05.016     Document Type: Article

References (71)

1. Ahlquist, R.P., Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J 92 (1976), 661–664.
2. Arrowsmith, C.H., Audia, J.E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P.E., Brown, P.J., Bunnage, M.E., et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11 (2015), 536–541.
3. Azzaoui, K., Jacoby, E., Senger, S., Rodriguez, E.C., Loza, M., Zdrazil, B., Pinto, M., Williams, A.J., de la Torre, V., Mestres, J., et al. Scientific competency questions as the basis for semantically enriched open pharmacological space development. Drug Discov. Today 18 (2013), 843–852.
4. Bassilana, F., Carlson, A., DaSilva, J.A., Grosshans, B., Vidal, S., Beck, V., Wilmeringwetter, B., Llamas, L.A., Showalter, T.B., Rigollier, P., et al. Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39. Nat. Chem. Biol. 10 (2014), 343–349.
5. Bateman, A., Coin, L., Durbin, R., Finn, R.D., Hollich, V., Griffiths-Jones, S., Khanna, A., Marshall, M., Moxon, S., Sonnhammer, E.L., et al. The Pfam protein families database. Nucleic Acids Res. 32 (2004), D138–D141.
6. Bolling, C., Weidlich, M., Holzhutter, H.G., SEE: structured representation of scientific evidence in the biomedical domain using Semantic Web techniques. J. Biomed. Semantics, 5, 2014, S1.
7. Bunnage, M.E., Chekler, E.L., Jones, L.H., Target validation using chemical probes. Nat. Chem. Biol. 9 (2013), 195–199.
8. Chen, B., Ding, Y., Wild, D.J., Assessing drug target association using semantic linked data. PLoS Comput. Biol., 8, 2012, e1002574.
9. Chen, B., Ding, Y., Wild, D.J., Improving integrative searching of systems chemical biology data using semantic annotation. J. Cheminform., 4, 2012, 6.
10. Cumming, J.G., Davis, A.M., Muresan, S., Haeberlein, M., Chen, H., Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discov. 12 (2013), 948–962.
11. Dai, Y., Grant, S., Cyclin-dependent kinase inhibitors. Curr. Opin. Pharmacol. 3 (2003), 362–370.
12. Dokmanovic, M., Clarke, C., Marks, P.A., Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5 (2007), 981–989.
13. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., Lydon, N.B., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996), 561–566.
14. Eggert, U.S., The why and how of phenotypic small-molecule screens. Nat. Chem. Biol. 9 (2013), 206–209.
15. Emig, D., Kacprowski, T., Albrecht, M., Measuring and analyzing tissue specificity of human genes and protein complexes. EURASIP J. Bioinform Syst. Biol., 2011, 2011, 5.
16. Feng, Y., Mitchison, T.J., Bender, A., Young, D.W., Tallarico, J.A., Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 8 (2009), 567–578.
17. Finn, R.D., Bateman, A., Clements, J., Coggill, P., Eberhardt, R.Y., Eddy, S.R., Heger, A., Hetherington, K., Holm, L., Mistry, J., et al. Pfam: the protein families database. Nucleic Acids Res. 42 (2014), D222–D230.
18. Frye, S.V., The art of the chemical probe. Nat. Chem. Biol. 6 (2010), 159–161.
19. Gambacorti-Passerini, C., Part I: milestones in personalised medicine—imatinib. Lancet Oncol., 9, 2008, 600.
20. Graczyk, P.P., Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J. Med. Chem. 50 (2007), 5773–5779.
21. Gregori-Puigjane, E., Setola, V., Hert, J., Crews, B.A., Irwin, J.J., Lounkine, E., Marnett, L., Roth, B.L., Shoichet, B.K., Identifying mechanism-of-action targets for drugs and probes. Proc. Natl. Acad. Sci. USA 109 (2012), 11178–11183.
22. Gryglewski, R.J., Korbut, R., Robak, J., Swies, J., On the mechanism of antithrombotic action of flavonoids. Biochem. Pharmacol. 36 (1987), 317–322.
23. Gujral, T.S., Peshkin, L., Kirschner, M.W., Exploiting polypharmacology for drug target deconvolution. Proc. Natl. Acad. Sci. USA 111 (2014), 5048–5053.
24. Hart, C.P., Finding the target after screening the phenotype. Drug Discov. Today 10 (2005), 513–519.
25. Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4 (2008), 682–690.
26. Hopkins, A.L., Drug discovery: predicting promiscuity. Nature 462 (2009), 167–168.
27. Huang, S.M., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461 (2009), 614–620.
28. Ishii, H., Jirousek, M.R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S.E., Kern, T.S., Ballas, L.M., Heath, W.F., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272 (1996), 728–731.
29. Jester, B.W., Gaj, A., Shomin, C.D., Cox, K.J., Ghosh, I., Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen. J. Med. Chem. 55 (2012), 1526–1537.
30. Jones, J.O., Diamond, M.I., Design and implementation of cell-based assays to model human disease. ACS Chem. Biol. 2 (2007), 718–724.
31. Jones, G.H., Scott, S.J., Continuous infusions of terbutaline in asthma—a review. J. Asthma 48 (2011), 753–756.
32. Kalliokoski, T., Kramer, C., Vulpetti, A., Gedeck, P., Comparability of mixed IC(5)(0) data—a statistical analysis. PLoS One, 8, 2013, e61007.
33. Kano, M.R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. USA 104 (2007), 3460–3465.
34. Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008), 127–132.
35. Kaya, A.I., Onaran, H.O., Ozcan, G., Ambrosio, C., Costa, T., Balli, S., Ugur, O., Cell contact-dependent functional selectivity of beta2-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation. J. Biol. Chem. 287 (2012), 6362–6374.
36. Keiser, M.J., Setola, V., Irwin, J.J., Laggner, C., Abbas, A.I., Hufeisen, S.J., Jensen, N.H., Kuijer, M.B., Matos, R.C., Tran, T.B., et al. Predicting new molecular targets for known drugs. Nature 462 (2009), 175–181.
37. King, F.J., Selinger, D.W., Mapa, F.A., Janes, J., Wu, H., Smith, T.R., Wang, Q.-Y., Niyomrattanakitand, P., Sipes, D.G., Brinker, A., Pathway reporter assays reveal small molecule mechanisms of action. J. Assoc. Lab. Autom. 14 (2009), 374–382.
38. Kramer, C., Kalliokoski, T., Gedeck, P., Vulpetti, A., The experimental uncertainty of heterogeneous public K(i) data. J. Med. Chem. 55 (2012), 5165–5173.
39. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42 (2014), D1091–D1097.
40. Lee, J.A., Uhlik, M.T., Moxham, C.M., Tomandl, D., Sall, D.J., Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 55 (2012), 4527–4538.
41. Lounkine, E., Keiser, M.J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J.L., Lavan, P., Weber, E., Doak, A.K., Cote, S., et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486 (2012), 361–367.
42. Moffat, J.G., Rudolph, J., Bailey, D., Phenotypic screening in cancer drug discovery - past, present and future. Nat. Rev. Drug Discov. 13 (2014), 588–602.
43. Narwal, M., Haikarainen, T., Fallarero, A., Vuorela, P.M., Lehtio, L., Screening and structural analysis of flavones inhibiting tankyrases. J. Med. Chem. 56 (2013), 3507–3517.
44. Nidhi, Glick, M., Davies, J.W., Jenkins, J.L., Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 46 (2006), 1124–1133.
45. Pei, X.H., Xiong, Y., Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 24 (2005), 2787–2795.
46. Riazanov, A., Klein, A., Shaban-Nejad, A., Rose, G.W., Forster, A.J., Buckeridge, D.L., Baker, C.J., Semantic querying of relational data for clinical intelligence: a semantic web services-based approach. J. Biomed. Semantics, 4, 2013, 9.
47. Riniker, S., Fechner, N., Landrum, G.A., Heterogeneous classifier fusion for ligand-based virtual screening: or, how decision making by committee can be a good thing. J. Chem. Inf. Model. 53 (2013), 2829–2836.
48. Riniker, S., Wang, Y., Jenkins, J.L., Landrum, G.A., Using information from historical high-throughput screens to predict active compounds. J. Chem. Inf. Model. 54 (2014), 1880–1891.
49. Roth, B.L., Sheffler, D.J., Kroeze, W.K., Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3 (2004), 353–359.
50. Ruegg, U.T., Burgess, G.M., Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci. 10 (1989), 218–220.
51. Ruttenberg, A., Clark, T., Bug, W., Samwald, M., Bodenreider, O., Chen, H., Doherty, D., Forsberg, K., Gao, Y., Kashyap, V., et al. Advancing translational research with the semantic web. BMC Bioinformatics, 8(Suppl 3), 2007, S2.
52. Sakiyama, Y., The use of machine learning and nonlinear statistical tools for ADME prediction. Expert Opin. Drug Metab. Toxicol. 5 (2009), 149–169.
53. Samwald, M., Jentzsch, A., Bouton, C., Kallesoe, C.S., Willighagen, E., Hajagos, J., Marshall, M.S., Prud'hommeaux, E., Hassenzadeh, O., Pichler, E., et al. Linked open drug data for pharmaceutical research and development. J. Cheminform., 3, 2011, 19.
54. Sankari, S.L., Babu, N.A., Rani, V., Priyadharsini, C., Masthan, K.M., Flavonoids - clinical effects and applications in dentistry: a review. J. Pharm. Bioallied Sci. 6 (2014), S26–S29.
55. Scheiber, J., Chen, B., Milik, M., Sukuru, S.C., Bender, A., Mikhailov, D., Whitebread, S., Hamon, J., Azzaoui, K., Urban, L., et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model 49 (2009), 308–317.
56. Schirle, M., Jenkins, J.L., Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov. Today 21 (2015), 82–89.
57. Shadbolt, N., Hall, W., Berners-Lee, T., The semantic web revisited. Ieee Intell. Syst. 21 (2006), 96–101.
58. Shapiro, G.I., Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (2006), 1770–1783.
59. Shin, Y.J., Kim, J.J., Kim, Y.J., Kim, W.H., Park, E.Y., Kim, I.Y., Shin, H.S., Kim, K.S., Lee, E.K., Chung, K.H., et al. Protective effects of quercetin against HgCl(2)-induced nephrotoxicity in Sprague-Dawley rats. J. Med. Food 18 (2015), 524–534.
60. Swinney, D.C., Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin. Pharmacol. Ther. 93 (2013), 299–301.
61. ++ dependent protein kinase. Biochem. Biophys. Res. Commun. 135 (1986), 397–402.
62. Tang, J., Szwajda, A., Shakyawar, S., Xu, T., Hintsanen, P., Wennerberg, K., Aittokallio, T., Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis. J. Chem. Inf. Model. 54 (2014), 735–743.
63. Tiikkainen, P., Bellis, L., Light, Y., Franke, L., Estimating error rates in bioactivity databases. J. Chem. Inf. Model. 53 (2013), 2499–2505.
64. Tsvetanova, N.G., von Zastrow, M., Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis. Nat. Chem. Biol. 10 (2014), 1061–1065.
65. Uitdehaag, J.C., Zaman, G.J., A theoretical entropy score as a single value to express inhibitor selectivity. BMC Bioinformatics, 12, 2011, 94.
66. Uitdehaag, J.C., Verkaar, F., Alwan, H., de Man, J., Buijsman, R.C., Zaman, G.J., A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 166 (2012), 858–876.
67. Violin, J.D., DiPilato, L.M., Yildirim, N., Elston, T.C., Zhang, J., Lefkowitz, R.J., beta(2)-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics. J. Biol. Chem. 283 (2008), 2949–2961.
68. Vita, J.A., Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am. J. Clin. Nutr. 81 (2005), 292S–297S.
69. Wild, D.J., Ding, Y., Sheth, A.P., Harland, L., Gifford, E.M., Lajiness, M.S., Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research. Drug Discov. Today 17 (2012), 469–474.
70. Williams, A.J., Harland, L., Groth, P., Pettifer, S., Chichester, C., Willighagen, E.L., Evelo, C.T., Blomberg, N., Ecker, G., Goble, C., et al. Open PHACTS: semantic interoperability for drug discovery. Drug Discov. Today 17 (2012), 1188–1198.
71. Workman, P., Collins, I., Probing the probes: fitness factors for small molecule tools. Chem. Biol. 17 (2010), 561–577.